129 related articles for article (PubMed ID: 3097710)
1. Fluphenazine activity and antipsychotic response.
Hitzemann RJ; Garver DL; Mavroidis M; Hirschowitz J; Zemlan FP
Psychopharmacology (Berl); 1986; 90(2):270-3. PubMed ID: 3097710
[TBL] [Abstract][Full Text] [Related]
2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
3. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
4. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
[TBL] [Abstract][Full Text] [Related]
5. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia.
Owen RR; Gutierrez-Esteinou R; Hsiao J; Hadd K; Benkelfat C; Lawlor BA; Murphy DL; Pickar D
Arch Gen Psychiatry; 1993 Aug; 50(8):636-44. PubMed ID: 8343034
[TBL] [Abstract][Full Text] [Related]
6. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
7. Fluphenazine plasma levels and clinical response.
Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
J Clin Psychiatry; 1984 Sep; 45(9):370-3. PubMed ID: 6381472
[TBL] [Abstract][Full Text] [Related]
8. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
[No Abstract] [Full Text] [Related]
9. High doses of fluphenazine enanthate in schizophrenia. A controlled study.
Dencker SJ; Johansson R; Lundin L; Malm U
Acta Psychiatr Scand; 1978 May; 57(5):405-14. PubMed ID: 354329
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
[TBL] [Abstract][Full Text] [Related]
12. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
[TBL] [Abstract][Full Text] [Related]
13. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
[TBL] [Abstract][Full Text] [Related]
14. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
Landmark J; Merskey H; Cernovsky ZZ
Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
[TBL] [Abstract][Full Text] [Related]
16. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
[TBL] [Abstract][Full Text] [Related]
17. Fluphenazine plasma levels and clinical response.
Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic effects on serine and glycine metabolism.
Baruah S; Waziri R; Sherman A
Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
[TBL] [Abstract][Full Text] [Related]
19. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
20. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
